我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
24
8 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
8
33.3%
已完成
5
20.8%
招募中
6
25.0%
终止
3
12.5%
Unknown
2
8.3%
暂无批准数据
- Imugene has activated its first Australian site for the Phase II Neo-POLEM trial, expanding recruitment for its PD1-Vaxx immunotherapy in both Australia and the United Kingdom. - The trial targets patients with mismatch repair-deficient or microsatellite instability-high colorectal cancer, a genetic subtype representing about 15% of colorectal cancer cases. - PD1-Vaxx is a neoadjuvant B-cell vaccine designed to trigger immune responses against PD-1, administered before surgery to evaluate major pathological response and tumor shrinkage. - Colorectal cancer affects more than 1.2 million new patients annually worldwide, with approximately 80% presenting with localized disease yet maintaining a 50% global mortality rate.
